NCT00399789 - A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

121

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2011

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG

Perifosine

Perifosine will be tested in 3 dose forms

Trial Locations (21)

10504

AOI Pharmaceuticals Investigative Site, Armonk

12208

AOI Pharmaceuticals Investigative Site, Albany

29605

AOI Pharmaceuticals Investigative Site, Greenville

30045

AOI Pharmaceuticals Investigative Site, Lawrenceville

32174

AOI Pharmaceuticals Investigative Site, Ormond Beach

33021

AOI Pharmaceuticals Investigative Site, Hollywood

33180

AOI Pharmaceuticals Investigative Site, Aventura

33805

AOI Pharmaceuticals Investigative Site, Lakeland

37203

AOI Pharmaceuticals Investigative Site, Nashville

37404

AOI Pharmaceuticals Investigative Site, Chattanooga

47150

AOI Pharmaceuticals Investigative Site, New Albany

49048

AOI Pharmaceuticals Investigative Site, Kalamazoo

49546

AOI Pharmaceuticals Investigative Site, Grand Rapids

59101

AOI Pharmaceuticals Investigative Site, Billings

61401

AOI Pharmaceuticals Investigative Site, Galesburg

75237

AOI Pharmaceuticals Investigative Site, Dallas

75246

AOI Pharmaceuticals Investigative Site, Dallas

75702

AOI Pharmaceuticals Investigative Site, Tyler

85704

AOI Pharmaceuticals Investigative Site, Tucson

87109

AOI Pharmaceuticals Investigative Site, Albuquerque

91767

AOI Pharmaceuticals Investigative Site, Pomona